Martin Bonde
Martin Bonde, CEO, Inthera Bioscience / Faculty at CBS Executive
Biography
CBS Executive
Martin Bonde is CEO of Swiss-based oncology company Inthera Bioscience AG. With 25+ years of international experience from the biotech industry, Martin has held several leadership positions as CEO for e.g. Vaccibody AS (now Nykode Therapeutics AS, Euronext Growth Oslo:VACC), Epitherapeutics Aps (sold to Gilead Sciences, Inc.), NatImmune A/S (sold to Azanta A/S), Combio A/S (sold to Arpida AG), Torsana Biosensor (sold to Celtor Bioscience, Inc.), and Osteometer Biotech (now Nordic Bioscience A/S). Martin serves on the Board of Directors in privately held digital pathology software company Visiopharm A/S and in BioInnovation Institute (BII), an international life science incubator funded by the Novo-Nordisk Foundation. Martin holds a Master of Science and Ph.D in Chemical Engineering from the Technical University of Denmark as well as a Graduate Diploma in Business Administration (HD i Udenrigshandel) from Copenhagen Business School.
Read about executive education
Other experts
Popular Courses
The Positive Leader: Deep Change and Organizational Transformation
Stephen M. Ross School of Business
Ann Arbor, Michigan, United States
Sep 29
Leading People and Teams
ESMT
Berlin, Germany
Nov 19
Private Equity: Investing and Creating Value
The Wharton School
Philadelphia, Pennsylvania, United States
Feb 2, 2025
Looking for an expert?
Contact us and we'll find the best option for you.